Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference
Picard Medical (NYSE American: PMI) announced its upcoming participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Picard Medical (NYSE American: PMI) announced its upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held from September 8-10, 2025, at the Lotte New York Palace Hotel in a hybrid format featuring both in-person and virtual sessions.
CEO Patrick NJ Schnegelsberg will deliver an in-person company presentation on September 10th at 1:30 pm. The presentation will be webcasted live and available for replay through Picard's website in the Investor Overview/Events section.
Details
News Market Reaction – PMI
On Sep 8, the day this news came out, PMI closed 13.85% above the previous close.
Data tracked by StockTitan Argus for the Sep 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel.
Presentation information is below:
H.C. Wainwright Annual Global Investment Conference
Presentation date: September 10th
Presentation time: 1:30 pm
Format: in-person; live, webcasted Company presentation with reply
To listen to the presentation live or via replay, please visit the Investor Overview/Events section of the Picard website here
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.